Global Pharmaceutical and Biotechnology Industry Boosts Confidence for Investors as the Market Expands

Companies are exploring new markets for innovative assets to add value to their pipeline, finds Frost & Sullivan

31-Jul-2015 - In recent years, the global pharmaceutical and biotechnology industry has outperformed other sectors in terms of stock market indices. The appeal of orphan drugs and systems that reduce the cost of healthcare will continue to attract investors to fund the industry.Analysis from Frost & Sullivan, ...

A Rise in IPOs Revive Investments for the Global Pharma and Biotech Industry

Oncology, anti-infective drugs, and pharmaceutical contract laboratories attract the most investment thus far

05-Jun-2014 - The heightened private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008-2010, witnessed a decline post-2010. However, the fall in deals was not uniform among the constituent sectors, with the pharmaceutical, biotechnology and ...

Is cloud the answer to healthcare industry’s challenges?

Healthcare providers foresee transformational cloud-based models emerging in the near future

04-Oct-2013 - Healthcare regimes all over the world are in crisis fighting diverse challenges including rising healthcare costs, aging populations, dynamic burden of diseases and increasing demand for accountable care. In response to these challenges healthcare stakeholders seek innovative technologies that ...

Impending Patent Expiries of Blockbuster Biologics Creates Huge Market Opportunity for European Biosimilars Manufacturers, States Frost & Sullivan

Seamlessly Integrated R&D, Production, Sales and Marketing Processes to Ensure Success in this High Growth Market

17-Feb-2012 - The biosimilars manufacturing industry is at a nascent stage. However, the impending patent expiries of biologics are anticipated to result in the introduction of several new biosimilars and provide impetus to market development.New analysis from Frost & Sullivan, Analysis of European Biosimilars ...

LEUKOCARE to receive Frost & Sullivan’s 2011 Biotechnology Investment Opportunity Award

16-Feb-2012 - LEUKOCARE has been awarded 2011’s “Biotechnology Investment Opportunity Award”, by the independent research consultancy Frost & Sullivan.In the citation for the 2011 European Biotechnology Industry Early Stage Investment Opportunity Award, Frost & Sullivan focuses on the innovative nature of ...

Frost & Sullivan: Plant Molecular Farming - a new Biotech Wave

Opportunities and Challenges in Europe in the Production of Biopharmaceuticals using Plant Molecular Farming

21-Dec-2011 - Currently, the two approved methods of Biopharmaceuticals manufacturing widely used in Europe are mammalian cell culture manufacturing and microbial fermentation. The high production and layout costs, bottlenecks in downstream processing, high vulnerability to microbial contamination, lengthy ...

Open Source Innovation Is Increasingly Being Used to Promote Innovation in the Drug Discovery Process and Boost Bottom Lines

23-Nov-2010 - The completion of the human genome project generated a plethora of complex information that launched the medical community into the next era of therapeutic intervention. New discoveries have led to the need for new ways to tap the vast amounts of information, so as to optimise its potential use. ...

Cost Benefits and Considerable Scientific Expertise Provide China Strategic Advantage for Drug Discovery Outsourcing

New analysis from Frost & Sullivan

21-Oct-2010 - With fast-paced advancements in genomics, combinatorial chemistry, and high-throughput screening, China has emerged as a major location to which drug discovery is being outsourced. China has the advantages of scientific expertise and comprehensive infrastructure, which are critical for drug ...

Demand from Western Europe and North America Fuels the Australian Biopesticides Market

24-Jun-2010 - Industrial (white) biotechnology is on the rise, with global sales of chemicals derived from industrial biotechnology estimated at €125 billion, or roughly 10 per cent of global chemical revenues. The largest segments of the market are speciality chemicals, biofuels and food and feed ingredients, ...

Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan

22-Oct-2009 - The global recession will have limited effect on the lifesciences industry. However, internal factors and external issues such as weak product pipelines, generic competition and declining market shares are pressurising lifesciences companies to cut down their IT budgets. New analysis from Frost & ...